AI Article Synopsis

Article Abstract

A multitude of studies has indicated the potential of cell therapy as a method for intervertebral disc (IVD) regeneration. Transplantation of a variety of cells has been assessed and shown capable of deterring the rate of degeneration in animal models and in human clinical trials. In this study, a novel approach using human discogenic nucleus pulposus cells directly from their cryopreserved state was assessed. In an established canine disc degeneration model, the degeneration process was evaluated in IVDs receiving precultured discogenic cells, thawed-only discogenic cells, and a saline sham injection after induction of degeneration. Degeneration progression was followed over time by the evaluation of the disc height index (DHI). Finally, after 12 weeks, the manipulated and control discs were explanted, histologically stained, and scored. Treated discs demonstrated retained DHI values for all treatment options. Histologic evaluations demonstrated significant improvement of matrix features compared to the sham. Moreover, thawed-only cells function at least as well as precultured discogenic cells. In short, cell transplantation of human discogenic cells directly from their cryopreserved state can arrest disc height degeneration and maintain histological matrix features in a canine disc degeneration model. The presented work demonstrates the potential of an off-the-shelf cell therapy product to treat degenerative disc disease.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6686803PMC
http://dx.doi.org/10.1002/jsp2.1013DOI Listing

Publication Analysis

Top Keywords

discogenic cells
16
directly cryopreserved
12
cryopreserved state
12
disc degeneration
12
cell transplantation
8
intervertebral disc
8
degeneration
8
cell therapy
8
human discogenic
8
cells directly
8

Similar Publications

Stem Cells Therapy as a Treatment for Discogenic Low Back Pain: A Systematic Review.

Int J Spine Surg

January 2025

Spine Consultant, Department of Orthopedic and Traumatology, Mayapada Hospital Kuningan, Jakarta, Indonesia.

Background: Low back pain (LBP) is 1 of the most common problems that present in 80% of people. LBP can be caused by some pathologies, with discogenic pain being 1 source. Pain from LBP can become chronic and also cause disability.

View Article and Find Full Text PDF

Intervertebral Disc Degeneration and Regeneration: New Molecular Mechanisms and Therapeutics: Obstacles and Potential Breakthrough Technologies.

Cells

December 2024

Department of Surgery, Divisions of Orthopaedic and Neurosurgery, University of Toronto, 661 University Ave., Suite 13-1387, Toronto, ON M5G 0B7, Canada.

Pain and disability secondary to degenerative disc disease continue to burden the healthcare system, creating an urgent need for effective, disease-modifying therapies. Contemporary research has identified potential therapies that include protein-, cellular- and/or matrix-related approaches; however, none have yet achieved a meaningful clinical impact. The tissue-specific realities of the intervertebral disc create considerable therapeutic challenges due to the disc's location, compartmentalization, hypovascularization and delicate physiological environment.

View Article and Find Full Text PDF
Article Synopsis
  • Recent research highlights the potential of biologic treatments like mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP) for relieving low back pain by promoting healing in intervertebral discs.
  • A systematic review and meta-analysis evaluated the effectiveness of MSC and PRP injections for chronic low back and leg pain, analyzing data from various credible sources.
  • The findings included 8 randomized controlled trials and 8 observational studies, revealing fair evidence quality but noting a lack of high-quality studies, suggesting a moderate recommendation for these treatments.
View Article and Find Full Text PDF
Article Synopsis
  • Intervertebral disc degeneration and pain are linked to the activation of the NLRP3 inflammasome and the processing of IL-1β, which involves Toll-like receptor stimulation and the CD14 receptor.
  • The peptide Short Link N (sLN) has shown promise in reducing inflammation and pain in disc cells, but its exact mechanisms of action are not fully understood.
  • This study found that sLN inhibited the activation of NFκB and Caspase-1, leading to lower levels of IL-1β, and demonstrated a direct interaction between sLN and CD14, suggesting sLN could be a potential treatment for disc-related pain.
View Article and Find Full Text PDF

Intervertebral disc (IVD) degeneration is a leading cause of lower back pain (LBP). Current treatments primarily address symptoms without halting the degenerative process. Cell transplantation offers a promising approach for early-stage IVD degeneration, but challenges such as cell viability, retention, and harsh host environments limit its efficacy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!